PTH and hyperphosphatemia: PHP1B is characterized by end-organ resistance to several endocrine hormones, including parathyroid hormone (PTH) leading to hypocalcaemia and hyperphosphatemia, and thyroid stimulating hormone (TSH) leading to clinical or subclinical hypoparathyroidism.